Hansa Medical Reports Positive Final Top Line Results from Two Phase 2 Studies of Imlifidase for Kidney Transplantation
· Imlifidase meets all primary and secondary endpoints in both studies · Treatment with imlifidase enables highly sensitized patients to receive lifesaving transplants · Hansa Medical plans to submit BLA and MAA filings in Q4 2018 or Q1 2019 · Company to host conference call today, September 27 2018 at 2pm CEST (5am PDT, 8am EDT, 1pm BST)Lund, Sweden, September 27, 2018- Hansa Medical AB (NASDAQ Stockholm: HMED), the leading biopharma company focusing on inhibition of immunoglobulin G (IgG)-mediated immunopathologies, announced today the successful completion of two Phase 2